Aligos Therapeutics Inc.
| NASDAQ: ALGS | Healthcare / Biotechnology / USA |
| 0.6910 | -0.0090 | -1.29% | Vol 62.19K | 1Y Perf -26.32% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 0.6700 | ASK | 0.7500 | ||
| Open | 0.6900 | Previous Close | 0.7000 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 2.54 | Analyst Rating | Moderate Buy 1.67 | |
| Potential % | 267.58 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 54.31 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 8.13 | Earnings Rating | — | |
| Market Cap | 51.78M | Earnings Date | 2nd Nov 2023 | |
| Alpha | -0.06 | Standard Deviation | 0.29 | |
| Beta | 2.20 |
Today's Price Range 0.68000.7500 | 52W Range 0.53882.41 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 1.62% | ||
| 1 Month | 7.97% | ||
| 3 Months | -21.05% | ||
| 6 Months | -39.39% | ||
| 1 Year | -26.32% | ||
| 3 Years | -96.31% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -73.16 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -57.83 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -61.77 | |||
Return on invested Capital Q | -13.37 | |||
Return on invested Capital Y | -63.46 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.50 | ||||
| 0.46 | ||||
| 4.98 | ||||
| - | ||||
| -0.90 | ||||
| -2.36 | ||||
| 0.46 | ||||
| 2.85 | ||||
| -73 182 600.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.70 | ||||
| 4.90 | ||||
| 0.07 | ||||
| 0.11 | ||||
| -11.50 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -1 051.00 | ||||
| -1 015.70 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.37M | ||||
| 0.26 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.48 | -0.41 | 14.58 |
| Q02 2023 | -0.50 | -0.43 | 14.00 |
| Q01 2023 | -0.49 | -0.53 | -8.16 |
| Q04 2022 | -0.49 | -0.51 | -4.08 |
| Q03 2022 | -0.57 | -0.44 | 22.81 |
| Q02 2022 | -0.65 | -0.47 | 27.69 |
| Q01 2022 | -0.66 | -0.84 | -27.27 |
| Q04 2021 | -0.83 | -0.89 | -7.23 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.48 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 62.19K |
| Shares Outstanding | 74.93K |
| Shares Float | 52.51M |
| Trades Count | 263 |
| Dollar Volume | 43.68K |
| Avg. Volume | 83.72K |
| Avg. Weekly Volume | 65.20K |
| Avg. Monthly Volume | 107.35K |
| Avg. Quarterly Volume | 78.59K |
Aligos Therapeutics Inc. (NASDAQ: ALGS) stock closed at 0.691 per share at the end of the most recent trading day (a -1.29% change compared to the prior day closing price) with a volume of 62.19K shares and market capitalization of 51.78M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 73 people. Aligos Therapeutics Inc. CEO is Lawrence M. Blatt.
The one-year performance of Aligos Therapeutics Inc. stock is -26.32%, while year-to-date (YTD) performance is -27.48%. ALGS stock has a five-year performance of %. Its 52-week range is between 0.5388 and 2.41, which gives ALGS stock a 52-week price range ratio of 8.13%
Aligos Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.46, a price-to-sale (PS) ratio of 4.98, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -57.83%, a ROC of -61.77% and a ROE of -73.16%. The company’s profit margin is -%, its EBITDA margin is -1 015.70%, and its revenue ttm is $10.37 Million , which makes it $0.26 revenue per share.
Of the last four earnings reports from Aligos Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.48 for the next earnings report. Aligos Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aligos Therapeutics Inc. is Moderate Buy (1.67), with a target price of $2.54, which is +267.58% compared to the current price. The earnings rating for Aligos Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aligos Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aligos Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.04, ATR14 : 0.09, CCI20 : 8.31, Chaikin Money Flow : -0.15, MACD : -0.01, Money Flow Index : 36.53, ROC : -5.28, RSI : 49.84, STOCH (14,3) : 55.17, STOCH RSI : 0.74, UO : 38.60, Williams %R : -44.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aligos Therapeutics Inc. in the last 12-months were: Nuechterlein Carole (Buy at a value of $6 545 221)
Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).
CEO: Lawrence M. Blatt
Telephone: +1 800 466-6059
Address: One Corporate Drive, South San Francisco 94080, CA, US
Number of employees: 73
TipRanks News for ALGS
Wed, 08 Nov 2023 06:22 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), Aligos Therapeutics (ALGS) and Nektar Therapeutics (NKTR)
- TipRanks. All rights reserved.
